Clinical Trials Logo

Ischemic Heart Disease clinical trials

View clinical trials related to Ischemic Heart Disease.

Filter by:

NCT ID: NCT03795714 Recruiting - Clinical trials for Ischemic Heart Disease

Association Between IVUS Parameters and Invasive Physiologic Indices

Start date: November 17, 2017
Phase:
Study type: Observational

1. to evaluate diagnostic accuracy and performance of IVUS-derived quantitative parameters to predict functional significance of stenosis defined using all the available physiologic indices. 2. to explores the association between IVUS-derived plaque characteristics and invasive physiologic indices.

NCT ID: NCT03791788 Recruiting - Clinical trials for Ischemic Heart Disease

Multicenter Registry for Angiography-Derived Quantitative Flow Ratio

QFRRegistry
Start date: November 30, 2018
Phase:
Study type: Observational

1. to investigate the feasibility and diagnostic performance of contrast quantitative flow ratio (QFR) for identifying the functional significance of intermediate degree stenotic lesions in all-comer patients with coronary artery disease (CAD) including presentation of acute myocardial infarction (AMI) with non-culprit lesion. 2. to compare the changes of contrast QFR and fractional flow reserve (FFR) according to severity of percent diameter stenosis (%DS)

NCT ID: NCT03786965 Recruiting - Clinical trials for Ischemic Heart Disease

Evaluating of Role of Myeloperoxidase in Prediction of Outcomes of Cardiac Surgery Procedures.

MPO-CSP
Start date: December 20, 2018
Phase: N/A
Study type: Interventional

The main objection is to investigate molecular biology of myocardial damage during cardiac surgery procedures.

NCT ID: NCT03786939 Recruiting - Clinical trials for Ischemic Heart Disease

Evaluation of Outcomes of Coronary Artery Bypass Grafting.

EOCABG
Start date: December 20, 2018
Phase: N/A
Study type: Interventional

Evaluation of outcomes of coronary artery bypass grafting.

NCT ID: NCT03780803 Recruiting - Clinical trials for Pulmonary Hypertension

Effect of Home Rehabilitation on State of Patients With PAH, HFREF and IHD

Start date: February 1, 2016
Phase: N/A
Study type: Interventional

The aim of the study is to evaluate the influence of physical training and respiratory rehabilitation performed by patients at home on quality of life, symptoms, physical endurance, force of respiratory and skeletal muscles and body mass composition in patients with pulmonary arterial hypertension (PAH) or left ventricular heart failure with reduced ejection fraction - HFREF), or ischemic heart disease and evaluation the number of stem cells, natural lymphoid cells and distribution of subpopulations of monocytes (including proangiogenic monocytes) in examined persons and evaluation of theirs eventual influence of the course of disease.

NCT ID: NCT03779217 Completed - Clinical trials for Cardiovascular Diseases

Breast Disease and Cardiovascular Disease

Start date: January 2, 2008
Phase:
Study type: Observational

Cardiovascular disease (CVD) occurs less frequently in women than in juvenile men.Frequently the estrogen deficiency associated with the menopausal state affects cardiovascular outcomes. In fact, in the post-menopausal state, even younger women may experience an increase in the rate of ischemic heart disease (IHD). On the other hand, CVD may also occur in premenopausal young women, due to not well known and/or not clearly investigated mechanisms. In addition, pre-menopausal women with IHD show atypical symptoms and more frequently myocardial infarction vs. angina pectoris. In detail, in these patients IHD is frequently due to mono-vessel coronary heart disease, and to the presence of cardiovascular risk factors such as hypertension, hyperlipidemia and type 2 diabetes. So, it is clear that all these pro-atherogenic risk factors which lead to IHD in women, are significantly lower in the pre-menopausal vs. post-menopausal patients. However, the causes leading to IHD and acute coronary events in pre-menopausal women remain poorly understood and poorly investigated, and these factors might be different from the traditional coronary risk factors evident in the general population. In this context, recently some authors have shown that subcutaneous abdominal fat affects cardiovascular performance at 1 year of follow-up in patients with normoglycemia vs. pre-diabetic. Therefore, here authors can hypothesize that in a population of female subjects, the fat tissue present in the mammary gland and the different degrees of mammary adipocyte infiltration can somehow invalidate the number of cardiovascular events in women of childbearing age. In detail, the different distribution of adipose tissue in the mammary gland can influence the density of the breast, as studied by mammographic examination, which is used to divide breast density into 4 different categories: - Category A: the breast is represented by 80% of fibro-glandular tissue and less than 20% by fat tissue. - Category B: the breast is represented by fibro-glandular tissue in the range of 50-75% and for the rest by fat tissue. - Category C: the breast is represented by fibro-glandular tissue in the range 25-50% and the rest is from fatty tissue. - Category D: the breast is represented by almost entirely fat tissue. Therefore, in the present study authors correlated the 4 different breast categories with CVD and 10-year follow-up IHD in women of child-bearing age. In fact, according to authors' opinion, a breast with higher fat density (category D) might influence the number of adverse cardiovascular events at 10-year follow-up in asymptomatic women. Thus, pre-menopausal women with breast tissue in category D as compared to women with prevalence of fibro-glandular tissue may have a higher frequency of adverse cardiac ischemic events at 10 years of follow-up.

NCT ID: NCT03772613 Not yet recruiting - Clinical trials for Coronary Artery Disease

The Randomized OPTIMAL-ACT Trial

Start date: January 2019
Phase: Phase 2
Study type: Interventional

Despite the widespread adoption of recommended anticoagulation intensity ranges during percutaneous coronary intervention (PCI), there are limited randomized clinical trials testing specific targets for activated clotting times (ACT). The primary research hypothesis is that in the modern cardiac catheterization laboratory, where PCI procedural duration is relatively short, radial access with small caliber equipment is preferable, and where rates of intracoronary stenting and dual antiplatelet therapy use is high, lower ACT targets, as compared with higher ACT targets, will be associated with lower rates of bleeding while having similar rates of ischemic events.

NCT ID: NCT03770520 Recruiting - Clinical trials for Coronary Artery Disease

Graft Patency of QFR-guided Versus Angio-guided Coronary Artery Bypass Grafting

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

Coronary artery bypass grafting(CABG) is the golden standard for severe coronary artery disease(CAD), the current surgery strategy is mainly based on coronary angiography(CAG), but many trials of PCI have shown that visually stenosis in CAG may not have functional significance. The aim of this study is to investigate if the Quantitative Flow Ratio (QFR) can be adopted in CABG and achieve a better graft patency.

NCT ID: NCT03700645 Not yet recruiting - Diabetes Mellitus Clinical Trials

Allopurinol in Diabetes Mellitus and Multivessel Coronary Artery Disease

Start date: December 1, 2018
Phase: Phase 4
Study type: Interventional

Atherosclerosis is a progressive disease of the arterial wall, arising from the combination of endothelial dysfunction and inflammation. This link is exacerbated in diabetic patients. Uric acid is known to generate oxidative stress and it's elevated levels has been shown to be associated with cardiac hypertrophy, inflammation, myocardial fibrosis and diastolic dysfunction. Allopurinol inhibits xanthine oxidase, an enzyme that regulates uric acid production. In observational studies it has been shown to reduce ischemia, inflammation and improve coronary flow. The aim of this study is to see whether treatment with Allopurinol in patients diagnosed with multivessel disease and undergoing treatment with either percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG) , will reduce markers of inflammation and improve quality of life and major adverse cardiovascular effects (MACE).

NCT ID: NCT03688815 Completed - Clinical trials for Ischemic Heart Disease

Dipyridamole Induced Ischemia and Biomarkers

Start date: January 1, 2009
Phase:
Study type: Observational

Analysis of certain biomarkers and transient myocardial perfusion deficit revealed by myocardial perfusion scintigraphy.